Selective Class I Phosphoinositide 3-Kinase Inhibitors: Optimization of a Series of Pyridyltriazines Leading to the Identification of a Clinical Candidate, AMG 511

Mark H. Norman(Amgen (United States)), Paul E. Hughes(Amgen (United States)), Xiaochun Zhu(Amgen (United States)), Victor J. Cee(Amgen (United States)), Nuria Tamayo(Amgen (United States)), Markian M. Stec(Amgen (United States)), Adrian L. Smith(Amgen (United States)), Bin Wu(China Astronaut Research and Training Center), Raju Subramanian(Gilead Sciences (United States)), Noel D. D’Angelo(Amgen (United States)), Nancy R. Zhang(University of the Arts), Anthony B. Reed(Amgen (United States)), Nobuko Nishimura(Amgen (United States)), Kevin Yang(Revolution Medicines (United States)), Seifu Tadesse(Amgen (United States)), Brian A. Lanman(Harvard University), Leeanne Zalameda(Amgen (United States)), Tisha San Miguel(Amgen (United States)), Bradley J. Herberich(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), Andrew S. Tasker(Amgen (United States)), Erin L. Mullady(Amgen (United States)), Claire Jackson(Babraham Institute), Liping H. Pettus(Amgen (United States)), Jian Jiang(Xuzhou Medical College), Shon K. Booker(Amgen (United States)), Longbin Liu(National University of Defense Technology), Divesh Aidasani(Amgen (United States)), Ling Wang(Guizhou University), Tian Wu(Guangzhou University of Chinese Medicine), Sean Caenepeel(Amgen (United States)), Kristin L. Andrews(Amgen (United States)), Yunxin Bo(Amgen (United States)), Daniel J. Freeman(Amgen (United States)), John D. McCarter(Amgen (United States)), Fang‐Tsao Hong(Amgen (United States)), Ryan P. Wurz(Amgen (United States))
Journal of Medicinal Chemistry
August 16, 2012
Cited by 50


Related Papers